Company news
Therma Bright Inc. (TSXV:THRM) news
Therma Bright Inc. news releases on 6ix. Latest, Nov 12, 2021: Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB…
Press releases — page 3
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
November 12, 2021
Therma Bright Provides Update on FDA-EUA Application Process
October 28, 2021
Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
October 4, 2021
Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF
September 14, 2021
Therma Bright Enters into Securities for Services Agreement, Debt Settlement, and Issues Options
August 12, 2021
Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test
August 5, 2021
Therma Bright Files Application to the OTCQB and DTC Clearing
July 29, 2021
IIROC Trading Resumption - THRM
July 22, 2021
Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results
July 22, 2021
IIROC Trading Halt - THRM
July 22, 2021
Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain
July 8, 2021
Therma Bright Secures US Distributor 'DME Authority' for Its Patented Venowave Lightweight Deep Vein Thrombosis (DVT) Device, Just as US Healthcare Providers Deal with Device Shortages
June 28, 2021
Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission
June 24, 2021
Therma Bright Reports Performance of Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study
June 17, 2021
Therma Bright Provides Update on Brazilian Clinical Study
May 27, 2021
Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
May 21, 2021
Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test
May 6, 2021
Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled
April 28, 2021
Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants
April 22, 2021
Therma Bright Announces EU-CE Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test and Conditional Sale for 100,000 CE-only AcuVid(TM) Test Kits
April 19, 2021
Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
April 13, 2021
Therma Bright Receives IRB Approval and Submits Application to Health Canada to Begin Clinical Study for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
March 25, 2021
Therma Bright Partners with Ridge Global to Expand Its United States and Global Reach
March 24, 2021
Therma Bright Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
March 18, 2021
Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
March 11, 2021
Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
February 26, 2021
Therma Bright Adds $1,171,875 to Treasury Through Exercise of Warrants and Options
January 29, 2021
Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test
January 25, 2021
Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies
January 18, 2021
Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe(TM)
January 15, 2021
Therma Bright Signs IR Agreement with Barwicki Investor Relations, Adds $300,000 to Treasury Through Exercise of Warrants and Options; and Grants Options
December 24, 2020
Therma Bright Achieves High Accuracy Results from Feasibility Studies for Its COVID-19 Rapid Saliva Test, CoviSafe(TM)
December 7, 2020
Therma Bright Creates New Venture, Torion Biosciences to Develop its COVID-19 Rapid Antigen Test, CoviSafe(TM)
November 4, 2020
Therma Bright and Orpheus Medica Advance CoviSafe(TM) Rapid Saliva Test to Formal Product Developmental Phase
October 21, 2020
Therma Bright and Orpheus Medica Secure Mitacs Funding to Support Its COVID-19 Research and Development Program
October 8, 2020
BTV Directs the Spotlight on Standout Companies in the Market
September 24, 2020
Therma Bright & Orpheus Medica to be Featured on BTV Business Television on BNN Bloomberg
September 23, 2020
Therma Bright and Orpheus Provide Development Update for its COVID-19 Rapid Saliva Test, CoviSafe(TM)
September 15, 2020
Therma Bright and Orpheus Identify Novel Biological Detection Molecules for COVID-19 Rapid Test
September 3, 2020
Therma Bright Provides Corporate Update
September 1, 2020
Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe(TM)
August 27, 2020
Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.
August 26, 2020
Therma Bright Provides Corporate Update on the Saringer and Orpheus Transactions
August 20, 2020
Therma Bright Completes Due Diligence of Orpheus Medica's CoviSafe(TM) COVID-19 Rapid Saliva Test and Moves to Phase 2
August 13, 2020
Therma Bright Announces Closing of Over-Subscribed Private Placement for $1,250,000
August 6, 2020
Therma Bright Inc. Unaware of Any Material Change
July 24, 2020
Therma Bright Increases Private Placement to $1,250,000 Due to Increased Demand
July 22, 2020
Therma Bright Announces up to $1,000,000 Private Placement Financing with Insider Participation and Debt Settlements
July 20, 2020
Therma Bright Provides Update on Orpheus Medica Rapid Test for COVID-19 Virus in Saliva - CoviSafe(TM)
July 16, 2020
Therma Bright Completes Due Diligence to Acquire Medical Device Technology from Saringer Life Science Technologies Inc.
July 9, 2020